[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Johnson & Johnson Enterprise Innovation Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":151},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,62,83,104,121],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100609794",false,"NCT07219212","A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma","A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma","LUMIRAY","Inclusion criteria:\n\n* Pathologically (histologically or cytologically) proven diagnosis of HNSCC of the oral cavity, oropharynx (p16 negative), hypopharynx, or supraglottic larynx\n* Stage III, IVA or IVB according to the 8th Edition of the American Joint Committee on Cancer (AJCC) guidelines\n* A candidate for definitive concurrent chemoradiation therapy treatment as determined by investigator and per local guidelines\n* Participants must have at least 1 target lesion (primary tumor or involved lymph node) per RECIST v.1.1\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1\n\nExclusion criteria:\n\n* Primary tumor originating in the nasopharynx, paranasal sinuses, salivary glands, thyroid gland, parathyroid gland, skin, or unknown primary site\n* Non-squamous histology\n* Stages 0, I, II, and IVC HNSCC, loco-regionally recurrent HNSCC, or synchronous second primary HNSCC (within 2 months)\n* Ineligible to receive platinum-based chemotherapy\n* Suspected or known allergies, hypersensitivity, or intolerance to JNJ-90301900 or its excipients","ALL","18 Years","74 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \\& throat).",[27],"Squamous Cell Carcinoma of Head and Neck","RECRUITING","2026-07-01",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":32},"2026-01-26",{"date":36,"type":21},"2028-07-14",{"name":38,"class":39},"Johnson & Johnson Enterprise Innovation Inc.","INDUSTRY",17,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100525057","NCT06116786","A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer","A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)\n* Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \\[EGFR\\], anaplastic lymphoma kinase \\[ALK\\], c-ros oncogene 1 \\[ROS1\\], v-raf murine sarcoma viral oncogene homolog B1 \\[BRAF\\]) must have received all approved targeted therapies and have progressed\n* Part 2: No targetable mutations (for example, EGFR \\[epidermal growth factor receptor\\], ALK \\[anaplastic lymphoma kinase\\], ROS1\\[c-ros oncogene 1\\], and BRAF \\[B-Raf proto-oncogene, serine\u002Fthreonine kinase\\])\n* Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy\n* For Cohort B of Part 2: Previously treated with anti-PD-1\u002FPD-L1 therapy for metastatic disease as the prior line of therapy\n* For Cohort C of Part 2: Treatment naïve\n* Adequate organ function\n\nExclusion Criteria:\n\n* Active central nervous system (CNS) disease involvement\n* Active autoimmune disease\n* Active infection\n* History of solid organ or hematologic stem cell transplantation",{"count":48,"type":21},126,[24],"The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.",[52],"Carcinoma, Non-small-Cell Lung","2026-06-19",{"date":55,"type":32},"2026-06-24",{"date":57,"type":32},"2023-11-27",{"date":59,"type":21},"2029-06-07",{"name":38,"class":39},15,{"id":63,"slug":4,"hasResults":10,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100633319","NCT07525141","A Study of JNJ-1761981 in Participants With Solid Tumors","Phase 1 Study of Intratumoral Administration of JNJ-1761981 ER, an Extended Release Chemotherapy, in Participants With Solid Tumors","Inclusion criteria:\n\n* Part 1: Individuals with a diagnosis of locally advanced or metastatic disease (solid tumors except tumors of the central nervous system \\[CNS\\]) who have previously received available standard therapy and progressed, or cannot tolerate standard therapy, or for whom there is no standard of care per regional guidelines\n* Part 2 Cohort A: Individuals with histologically or cytologically confirmed metastatic tumors of adenocarcinoma or squamous cell carcinoma histology, for which any platinum-based systemic regimen is considered a standard of care (per national comprehensive cancer network \\[NCCN\\] guidelines) and whose disease has progressed after standard therapy\n* Eastern cooperative oncology group performance status (ECOG) performance status of Grade 0 or 1\n* Part 2 Cohort A participants planned to receive optional cetrelimab (participants not meeting this criterion may still be enrolled in the study but cannot receive cetrelimab): Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy\n* A participant of childbearing potential must practice at least 2 highly effective methods of contraception throughout the study and through 14 months (for women) and 11 months (for men) after the last dose of JNJ-1761981 or 5 months after the last dose of cetrelimab or other anti-PD(L)1 treatment, whichever is later\n\nExclusion criteria:\n\n* Active symptomatic disease involvement of the central nervous system\n* Prior or concurrent second malignancy (other than the disease under study) that due to natural history or treatment is likely to interfere with any study endpoints of safety or the antitumor activity of the study treatment(s)\n* Active bleeding diathesis or requirement for therapeutic anticoagulation that cannot be interrupted or altered for procedures\n* Known allergies, hypersensitivity, or intolerance to JNJ-1761981 or its excipients\n* Lesions invading or adjacent to major blood vessels or other critical structures (for example, airways) not suitable for injection",{"count":69,"type":21},66,[24],"The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.",[73],"Neoplasms","2026-06-04",{"date":76,"type":32},"2026-06-05",{"date":78,"type":32},"2026-05-26",{"date":80,"type":21},"2029-01-31",{"name":38,"class":39},2,{"id":84,"slug":4,"hasResults":10,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100567416","NCT06667908","A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC","CONVERGE","Inclusion Criteria:\n\n* Must be a candidate for standard of care (SOC) treatment of non small cell lung cancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation durvalumab treatment as determined by the investigator and per local guidelines at screening\n* Have a medical history of pathologically (histologically or cytologically) proven diagnosis of NSCLC within 3 months prior to enrollment\u002Frandomization\n* Have locally advanced unresectable stage III NSCLC according to the eighth edition lung cancer stage classification\n* Have at least 1 target lesion (primary lung lesion or involved lymph node\\[s\\]) per RECIST version 1.1 that is amenable to intratumoral and\u002For intranodal injection and intensity modulated radiation therapy (IMRT) as determined by the investigator at screening\n* Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1\n\nExclusion Criteria:\n\n* Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requires therapeutic immunosuppression\n* Any of the following within 3 months prior to enrollment\u002Frandomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV\n* Another concurrent or prior primary malignancy within the last 36 months at informed consent\n* Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900 crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab\n* History of coagulation disorders, including: (a) Active bleeding diathesis or requirement for therapeutic anticoagulation or antiplatelet that cannot be interrupted or altered for JNJ-90301900 injection procedures, (b) Major thromboembolic events (for example, pulmonary embolism, cerebrovascular accident) within 3 months of enrollment or randomization",{"count":91,"type":21},130,[93],"PHASE2","The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.",[96],"Carcinoma, Non-Small-Cell Lung",{"date":76,"type":32},{"date":99,"type":32},"2024-12-06",{"date":101,"type":21},"2028-12-31",{"name":38,"class":39},41,{"id":105,"slug":4,"hasResults":10,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100540033","NCT06311578","A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors","Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors","Inclusion Criteria:\n\n* For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy; Part 2: Individuals with histologically or cytologically confirmed metastatic or locally advanced NSCLC\n* Have at least 1 injectable tumor\n* Eastern cooperative oncology group (ECOG) performance status of grade 0 or 1\n* A participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study\n* Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy\n\nExclusion Criteria:\n\n* Active disease involvement of the CNS (example, primary central nervous system tumors, metastases, leptomeningeal disease). Some exceptions are allowed\n* Prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy\n* Active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents\n* History of solid organ or hematologic stem cell transplantation\n* Known positive test result for human immunodeficiency virus (HIV) or other immunodeficiency syndrome\n* History of allergy to protein-based therapies or history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia)",{"count":48,"type":21},[24],"The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.",[73],{"date":76,"type":32},{"date":116,"type":32},"2024-04-10",{"date":118,"type":21},"2032-08-26",{"name":38,"class":39},10,{"id":122,"slug":4,"hasResults":10,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":10,"sex":16,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},"100430983","NCT04892173","JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Age greater than or equal to (\\>=) 60 years old\n* Biopsy-confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or supraglottic larynx and a candidate for definitive radiation therapy with or without cetuximab\n* Clinical stage T3-4 NX or T2 N2-3 disease according to the 8th edition of AJCC\n* One primary tumor lesion amendable for intratumoral injection\n* Ineligible to receive platinum-based chemotherapy with radiation (at least one of the following):\n\n  1. Estimated creatinine clearance \\>= 30 and less than (\\\u003C) 50 milliliters\u002Fminute (mL\u002Fmin) (per Cockcroft-Gault equation),\n  2. Grade \\>= 2 hearing loss or tinnitus,\n  3. Grade \\>= 2 peripheral neuropathy,\n  4. New York Heart Association Class 3\n  5. Aged 70-74 years old with Geriatric 8 (G8) score less than or equal to (\\\u003C=) 14 or Aged \\>= 75 years old\n* Eastern cooperative oncology group (ECOG) performance status 0 to 1\n* Life expectancy \\>= 6 months\n\nExclusion Criteria:\n\n* Carcinoma of the nasopharynx, paranasal sinus, salivary gland, or thyroid gland; or non-squamous histology or SCC of unknown primary origin\n* Clinical stage T1-2 N0, T2 N1, or M1 disease according to the 8th edition of AJCC\n* Loco-regionally recurrent head \\& neck cancer that has been previously treated with surgery, radiation therapy, and\u002For chemotherapy\n* Prior or concurrent primary malignancy (including second synchronous head \\& neck cancer) within the last 2 years of informed consent and whose natural history has the potential to interfere with the safety and efficacy assessment of the investigational agent\n* Ongoing or active infection requiring treatment with antimicrobial therapy within 2 weeks of randomization","60 Years",{"count":129,"type":21},500,[131],"PHASE3","This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) \u002F radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).",[134],"Carcinoma, Squamous Cell",[136,137,138,139,140,141,142,143],"LA-HNSCC","NBTXR3","hafnium oxide","radioenhancer","Radiotherapy","RT","HNSCC","radiation therapy",{"date":76,"type":32},{"date":146,"type":32},"2021-12-10",{"date":148,"type":21},"2028-06-30",{"name":38,"class":39},191,""]